OCUGEN, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
OCUGEN, INC. (OCGN) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $7.00 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2020-11-06
- OCUGEN, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-09-30 was $7.00M.
- OCUGEN, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2016 was $200.00K, a 35.48% decline from fiscal 2015.
- OCUGEN, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2015 was $310.00K, a 416.67% increase from fiscal 2014.
- OCUGEN, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2014 was $60.00K.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2020-09-30 | $7.00M 10-Q · filed 2020-11-06 | $7.00M 10-Q · filed 2020-11-06 | |
| 2016-12-31 | $200.00K 10-K · filed 2018-03-15 | ||
| 2015-12-31 | $310.00K 10-K · filed 2017-03-16 | ||
| 2014-12-31 | $60.00K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |